Combined Androgen Blockade in the Treatment of Advanced Prostate Cancer–an Overview

References

• Bartsch W, Knabble C, Voigt K-D. Regulation and compartmentalization of androgens in rat prostate and muscle. J Steroid Biochem 1983; 19: 929–937
   PubMedGoogle Scholar
• Bertagna C, De Gery A, Hucher M, Francois J P, Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer, A meta-analysis of seven randomised double-blind trials (1,056 patients). Br J Urol 1994; 73: 396–402
   PubMedGoogle Scholar
• Blumenstein B A. Some statistical considerations for the interpretation of trials of combined androgen therapy. Cancer 1993; 72: 3834–3840
   PubMed Web of Science ®Google Scholar
• Blumenstein B A. Overview analysis issues using combined androgen deprivation overview analysis as an example. Urol Oncol 1995; 1: 95–100
   PubMedGoogle Scholar
• Bracci U. Present procedures in the treatment of prostatic cancer. Hormonal therapy of prostatic cancer, U Bracci, F Silverio. Coffese, Palermo 1977; 177–192
   Google Scholar
• Crawford E D, DeAntonio E P, Labrie F, Schroder F H, Geller J. Endocrine therapy of prostate cancer: optimal form and appropriate timing. J Clin Endocrinol Metab 1995; 60: 1062–1078
   Google Scholar
• Crawford E D, Eisenberger M A, McLeod D G, Dorr F A, Davis A. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–424
   PubMed Web of Science ®Google Scholar
• Dawson N A, McLeod D G. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153: 1946–1947
   PubMed Web of Science ®Google Scholar
• Debruyne F MJ, Dijkman G A. Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 1995; 28: 177–188
   PubMed Web of Science ®Google Scholar
• Denis L. Endocrine treatment–should it be total (maximal) blockade?. Questions and uncertainties about prostate cancer, W B Peeling. Blackwell Science, Oxford 1996; 246–254
   Google Scholar
• Denis L J, Carneiro De Moura J L, Bono A, et al. goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993; 42: 119–130
   PubMed Web of Science ®Google Scholar
• Denis L, Murphy G P. Third international workshop on randomized trials on maximal androgen blockade in Ml prostate cancer patients. Cancer 1993; 72: 119–129
   Web of Science ®Google Scholar
• Geller J, Albert J. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res 1987; 15: 151–153
   PubMedGoogle Scholar
• Geller J, Albert J D, Nachtsheim D A, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984; 132: 693–696
   PubMed Web of Science ®Google Scholar
• Geller J, Albert J, Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 1988; 15: 53–61
   PubMed Web of Science ®Google Scholar
• Harper M E, Pike A, Peeling W B, et al. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974; 60: 117–125
   PubMed Web of Science ®Google Scholar
• Huggins C, Scott W W. Bilateral adrenalectomy in prostate cancer. Ann Surg 1945; 122: 1031–1041
   Web of Science ®Google Scholar
• Iversen P, Christensen M G, Friis E. et al. A Phase III trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990; 66: 1058–1066
   PubMed Web of Science ®Google Scholar
• Iversen P, Kaisary A V, Tyrrell C, et al. A randomised comparison of Casodex 150 mg versus castration in the treatment of advanced prostate cancer. Presented at the First International Consultation on Prostate Cancer. Patronized by WHO and UICC, Monaco, June, 1996
   Google Scholar
• Janknegt R A, Abbou C C, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77–83
   PubMed Web of Science ®Google Scholar
• Jørgensen T, Tveter K J, Jørgensen L H. SPCG-2 group. Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2. Eur Urol 1993; 24: 466–470
   PubMed Web of Science ®Google Scholar
• Klijn J GM, de Voogt H J, Studer U E, Schroder F H, Sylvester R, de Pauw M. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. Cancer 1993; 72: 3858–3869
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Belanger A. Complete androgen blockade for the treatment of prostate cancer. Important advances in oncologv, V T DeVita, S Hellman, S A Rosenberg. JP Lippincott, Philadelphia 1985; 193–217
   Google Scholar
• Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993; 16: 475–492
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579–594
   PubMed Web of Science ®Google Scholar
• Leuprolide Study Group. Leuprolide versus diethylstil-bestrol for metastatic prostate cancer. N Eng J Med 1984; 311: 1291–1286
   Web of Science ®Google Scholar
• Parker L N. Adrenal androgens in clinical medicine. Academic Press, New York 1989; 435–447, chapt. 25
   Google Scholar
• Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265–269
   PubMed Web of Science ®Google Scholar
• Scher H I, Kelly W K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566
   PubMed Web of Science ®Google Scholar
• Small E J, Carroll P R. Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408
   PubMed Web of Science ®Google Scholar
• Thorpe S C, Azmatullah S, Fellows G J, Gingell J C, O'Boyle P J. A prospective, randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47–54
   PubMed Web of Science ®Google Scholar
• Tyrrell C J, Altwein J E, Klippel F, et al. A multicentre randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol 1991; 146: 1321–1326
   PubMed Web of Science ®Google Scholar
• Waxman J, Man A, Hendry W F, et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J 1985; 291: 1387–1388
   PubMed Web of Science ®Google Scholar